MM-567 Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk

Autor: Mina, Roberto, Dhakal, Binod, San-Miguel, Jesus, Kwon, Mi, Purtill, Duncan, Magen, Hila, Dutka, Magdalena, Delforge, Michel, Vij, Ravi, Wichert, Stina, Yoon, Sung-Soo, Minnema, Monique C., Lendvai, Nikoletta, Lonardi, Carolina, Slaughter, Ana, Vogel, Martin, Li, Katherine, Chen, Diana, Zhao, Man, Yeh, Tzu-min, Benachour, Nina, Lengil, Tamar, Koneru, Mythili, Patel, Nitin, Florendo, Erika, Costa Filho, Octavio, Einsele, Hermann, Manier, Salomon, Martinez-Lopez, Joaquin
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S572-S573
Databáze: ScienceDirect
Externí odkaz: